Hibiskus' lead preclinical molecule is a potent, irreversible hybrid cyclic peptide proteasome inhibitor with anticancer properties. The molecule differs structurally from other marketed proteasome inhibitors, according to Lodo. In a clinical trial earlier this year, the candidate proved to be more effective than other marketed proteasome inhibitors in targeting resistant multiple myeloma and mantle cell lymphoma.

Lodo also announced the attainment of exclusive global rights to preclinical proteasome and immunoproteasome inhibitors developed by the Hibiskus co-founders. The rights were previously owned by the University of California, Riverside and Michigan State University.

The two acquisitions set Lodo up to consolidate Hibiskus' proteasome inhibitor portfolio and intellectual property with the company's own expertise and early-stage research, according to the company. One of the Hibiskus co-founders, Michael Pirrung, PhD, serves as a member on Lodo's Scientific Advisory Board.

As part of the deal, Lodo has renamed Hibiskus' lead preclinical molecule from TIR-199 to LODO-141. The company plans to begin clinical testing with candidates from two different initiatives in 2023.

Eli Lilly, Innovent expand immuno-oncology licensing
Eli Lilly and Innovent Biologics have agreed to a global expansion of their strategic alliance for Tyvyt (sintilimab injection), an anti-programmed cell...

Avectas, ONK to develop cancer cell therapy
Avectas has exclusively licensed a chimeric antigen receptor-directed natural killer cell therapy from ONK Therapeutics for the treatment of B-cell malignancies...